Study of an experimental drug for advanced tumors with MSI-H or dMMR
Part of Cancer clinical trials.
This trial tests an experimental drug called QLS1317 for people with advanced solid tumors that have a specific genetic marker (MSI-H or dMMR) and have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your tumor must have a specific genetic feature called MSI-H or dMMR, and you must have tried standard treatment that didn't work.
- You need to be able to take medication by mouth.
- You should be in reasonably good health (able to care for yourself and up and about more than half of your waking hours).
- You must not have cancer that has spread to your brain (unless it's been treated and is stable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, QLS-1304, for people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the drug is safe and effective.
This study tests an experimental drug called QLS5132 for people with advanced solid tumors (cancers that start in organs or tissues). The drug targets a protein called CLDN6 on some cancer cells and might help stop the tumor from growing.
This trial tests a new drug called QLS5133 for people with advanced solid tumors (cancers that have spread). The drug may help shrink tumors or slow their growth. The study is in two phases to find the right dose and see how well it works.
This trial tests an experimental drug called QLS5316 in people with advanced solid tumors that have stopped responding to standard treatment or for which no standard treatment exists. The goal is to find the right dose and see how well it shrinks or controls the cancer.
This trial tests an experimental drug (called QLS5308) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug can shrink tumors or slow their growth, and to find the best dose with manageable side effects.
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
Hear when a new MSI-H or dMMR Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.